BioSpace News Archive

Legal firms are lining up to lead litigation against the company on behalf of shareholders who saw their stock dive.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer.

Harvard Bioscience, Inc. announced financial results for the three and six months ended June 30, 2021.

PepGen, Inc., a company developing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, announced the closing of an oversubscribed $112.5 million crossover financing, led by a strong syndicate of investors.

Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, reported positive top-line results from the Phase 2 REPAIR clinical trials investigating the improvement of brain energetic metabolism in Parkinson’s disease and multiple sclerosis.

Kraig Biocraft Laboratories, Inc., the leading developer of spider silk based fibers, announces that the Company has further expanded its leading position in the development of recombinant spider silk with the filing of two new patent applications.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced its financial results for the second quarter of 2021 and provided a corporate update.

Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced financial results for the quarter ended June 30, 2021.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, provided a corporate and financial update for the second quarter ended June 30, 2021.